Video
Atezolizumab Plus Chemoradiation Provides No Survival Benefit in LS-SCLC
MRD Negativity Is Sustained After Cessation of Lenalidomide Maintenance in Multiple Myeloma
Locally Produced CAR T-Cell Therapy Elicits 92% ORR in Relapsed/Refractory Myeloma
Dr Dhakal on Survival and Safety Outcomes With Cilta-Cel in R/R Myeloma
2 Commerce Drive
Cranbury, NJ 08512